Vaxcyte appoints John P. Furey to Board of Directors, effective July 2, 2024

Vaxcyte, Inc.

John P. Furey appointed as Class II director; term expires at 2025 annual meeting.
Furey received initial stock option valued at $800,000 vested over 36 months; also joins Compensation Committee.
Annual equity awards of $450,000 (75% option, 25% RSU) and cash retainers of $50,000 board / $7,500 committee.
Indemnification agreement executed; Furey qualifies as independent director under Nasdaq rules.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John P. Furey

Class II director

PCVX · Vaxcyte, Inc.

Effective: 2024-07-02
Filed: July 2, 2024, 7:59 PM ET

the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed John P. Furey to the Board as a Class II director, which appointment became effective on July 2, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John P. Furey was appointed as Class II director at Vaxcyte, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed John P. Furey to the Board as a Class II director, which appointment became effective on July 2, 2024.

View on SEC.gov

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-174317

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.